Brokerages Set SI-BONE, Inc. (NASDAQ:SIBN) PT at $22.67

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have received a consensus rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have covered the stock in the last year is $22.67.

Several brokerages recently weighed in on SIBN. Truist Financial cut their price objective on shares of SI-BONE from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. Needham & Company LLC cut their price target on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Morgan Stanley decreased their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th.

Insider Buying and Selling

In other news, insider Anthony J. Recupero sold 3,305 shares of SI-BONE stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares in the company, valued at approximately $3,169,734.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other SI-BONE news, insider Anthony J. Recupero sold 3,905 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $13.84, for a total value of $54,045.20. Following the completion of the sale, the insider now directly owns 238,804 shares of the company’s stock, valued at $3,305,047.36. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 3,305 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total transaction of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares of the company’s stock, valued at $3,169,734.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,676 shares of company stock worth $344,967 in the last quarter. 5.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On SI-BONE

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of SI-BONE by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock worth $40,328,000 after acquiring an additional 43,670 shares during the period. Champlain Investment Partners LLC lifted its position in SI-BONE by 104.8% in the first quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock worth $40,158,000 after purchasing an additional 1,255,610 shares during the period. American Century Companies Inc. boosted its stake in SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after buying an additional 368,637 shares in the last quarter. Paradigm Capital Management Inc. NY increased its holdings in SI-BONE by 24.7% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock valued at $17,448,000 after buying an additional 267,100 shares during the period. Finally, Bellevue Group AG increased its holdings in SI-BONE by 810.5% in the 1st quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock valued at $18,661,000 after buying an additional 1,014,756 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

SI-BONE Stock Up 4.8 %

SI-BONE stock opened at $13.80 on Tuesday. The firm’s 50 day moving average price is $14.45 and its two-hundred day moving average price is $14.35. The firm has a market cap of $575.38 million, a PE ratio of -12.66 and a beta of 1.22. SI-BONE has a twelve month low of $11.76 and a twelve month high of $21.70. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 9.17.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04. SI-BONE had a negative return on equity of 24.27% and a negative net margin of 27.10%. The business had revenue of $39.97 million during the quarter, compared to analyst estimates of $38.95 million. During the same period last year, the company earned ($0.30) earnings per share. On average, research analysts predict that SI-BONE will post -0.89 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.